open access

Vol 29, No 3 (2022)
Original Article
Submitted: 2021-10-26
Accepted: 2022-05-06
Published online: 2022-05-13
Get Citation

Use of single pill combinations in the treatment of arterial hypertension in Poland: The current practice and guidelines, the impact on reimbursement spending and patient co-payment

Marcin Czech1, Stefan Boguslawski2, Anna Smaga2, Krzysztof J. Filipiak3
DOI: 10.5603/CJ.a2022.0031
·
Pubmed: 35578761
·
Cardiol J 2022;29(3):405-412.
Affiliations
  1. Department of Pharmacoeconomics, the Institute of Mother and Child, Warsaw, Poland
  2. Department of Population Health Monitoring and Analysis, the National Institute of Public Health NIH — National Research Institute, Warsaw, Poland
  3. Maria Sklodowska-Curie Medical Academy, Warsaw, Poland

open access

Vol 29, No 3 (2022)
Original articles — Clinical cardiology
Submitted: 2021-10-26
Accepted: 2022-05-06
Published online: 2022-05-13

Abstract

Background: Clinical guidelines recommend using single pill combinations (SPC) when initiating and intensifying the treatment of arterial hypertension (AH), which is not reflected in the Summaries of Product Characteristics (SMPC) for individual preparations. The drug reimbursement system in Poland (with a few exceptions) does not provide for reimbursement outside the indications specified in the SMPC. Therefore, it excludes the use of SPC under reimbursement. In 2020 the share of SPC in the treatment of AH amounted to 12.8% of unit volume and was lower than the 80% based on the guidelines of the Polish Society of Hypertension.
Methods: Using the data from a sample of pharmacies in Poland over the period November–December 2020, the potential was assessed of switching from existing AH therapy with monocomponent drugs containing selected combinations of active ingredients to the equivalent SPC.
Results: The potential of switching from AH treatment in the analyzed period using monocomponent drugs with the equivalent SPC amounted to 19% of unit volume (a reduction of 212M units), with the highest switch potential (43.9%) for drugs containing amlodipine. The public payer’s savings would be EUR 12.3 million and patient savings would amount to EUR 5.0 million.
Conclusions: Enabling reimbursement of SPC in Poland in line with the clinical guidelines can significantly increase the share of SPC in the treatment of AH, which will result in better health outcomes and a significant reduction in the payer’s drug reimbursement spending and will lower the financial barrier for patients to access this type of treatment.

Abstract

Background: Clinical guidelines recommend using single pill combinations (SPC) when initiating and intensifying the treatment of arterial hypertension (AH), which is not reflected in the Summaries of Product Characteristics (SMPC) for individual preparations. The drug reimbursement system in Poland (with a few exceptions) does not provide for reimbursement outside the indications specified in the SMPC. Therefore, it excludes the use of SPC under reimbursement. In 2020 the share of SPC in the treatment of AH amounted to 12.8% of unit volume and was lower than the 80% based on the guidelines of the Polish Society of Hypertension.
Methods: Using the data from a sample of pharmacies in Poland over the period November–December 2020, the potential was assessed of switching from existing AH therapy with monocomponent drugs containing selected combinations of active ingredients to the equivalent SPC.
Results: The potential of switching from AH treatment in the analyzed period using monocomponent drugs with the equivalent SPC amounted to 19% of unit volume (a reduction of 212M units), with the highest switch potential (43.9%) for drugs containing amlodipine. The public payer’s savings would be EUR 12.3 million and patient savings would amount to EUR 5.0 million.
Conclusions: Enabling reimbursement of SPC in Poland in line with the clinical guidelines can significantly increase the share of SPC in the treatment of AH, which will result in better health outcomes and a significant reduction in the payer’s drug reimbursement spending and will lower the financial barrier for patients to access this type of treatment.

Get Citation

Keywords

hypertension, treatment, single pill combination

About this article
Title

Use of single pill combinations in the treatment of arterial hypertension in Poland: The current practice and guidelines, the impact on reimbursement spending and patient co-payment

Journal

Cardiology Journal

Issue

Vol 29, No 3 (2022)

Article type

Original Article

Pages

405-412

Published online

2022-05-13

Page views

4333

Article views/downloads

488

DOI

10.5603/CJ.a2022.0031

Pubmed

35578761

Bibliographic record

Cardiol J 2022;29(3):405-412.

Keywords

hypertension
treatment
single pill combination

Authors

Marcin Czech
Stefan Boguslawski
Anna Smaga
Krzysztof J. Filipiak

References (25)
  1. Tsioufis K, Kreutz R, Sykara G, et al. Impact of single-pill combination therapy on adherence, blood pressure control, and clinical outcomes: a rapid evidence assessment of recent literature. J Hypertens. 2020; 38(6): 1016–1028.
  2. Weisser B, Predel HG, Gillessen A, et al. Single pill regimen leads to better adherence and clinical outcome in daily practice in patients suffering from hypertension and/or dyslipidemia: results of a meta-analysis. High Blood Press Cardiovasc Prev. 2020; 27(2): 157–164.
  3. Sicras Mainar A, Galera Llorca J, Muñoz Ortí G, et al. [Influence of compliance on the incidence of cardiovascular events and health costs when using single-pill fixed-dose combinations for the treatment of hypertension]. Med Clin (Barc). 2011; 136(5): 183–191.
  4. Kawalec P, Holko P, Stawowczyk E, et al. Economic evaluation of single-pill combination of indapamide and amlodipine in the treatment of arterial hypertension in the Polish setting. Kardiol Pol. 2015; 73(9): 768–780.
  5. Baser O, Andrews LM, Wang Li, et al. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy. J Med Econ. 2011; 14(5): 576–583.
  6. Wierzejska E, Giernaś B, Lipiak A, et al. A global perspective on the costs of hypertension: a systematic review. Arch Med Sci. 2020; 16(5): 1078–1091.
  7. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33): 3021–3104.
  8. Tykarski A, Filipiak KJ, Januszewicz A, et al. Zasady postępowania w nadciśnieniu tętniczym — 2019 rok Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce. 2019; 5(1): 1–86.
  9. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure In Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71(6): e13–e115.
  10. Yusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020; 395(10226): 795–808.
  11. Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020; 75(6): 1334–1357.
  12. Waśkiewicz A, Zujko ME, Szcześniewska D, et al. Polyphenols and dietary antioxidant potential, and their relationship with arterial hypertension: A cross-sectional study of the adult population in Poland (WOBASZ II). Adv Clin Exp Med. 2019; 28(6): 797–806.
  13. Hering D, Szymański FM. Comparison of hypertension epidemiology and treatment in Poland and Australia. Kardiol Pol. 2018; 76(3): 520–528.
  14. Yang Q, Cogswell ME, Flanders WD, et al. Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. JAMA. 2012; 307(12): 1273–1283.
  15. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016; 387(10017): 435–443.
  16. Niklas A, Flotyńska A, Puch-Walczak A, et al. Prevalence, awareness, treatment and control of hypertension in the adult Polish population - Multi-center National Population Health Examination Surveys - WOBASZ studies. Arch Med Sci. 2018; 14(5): 951–961.
  17. Filipiak KJ, Tomaniak M, Płatek AE, et al. Negative predictors of treatment success in outpatient therapy of arterial hypertension in Poland. Results of the CONTROL NT observational registry. Kardiol Pol. 2018; 76(2): 353–361.
  18. Rossier BC, Bochud M, Devuyst O. The hypertension pandemic: an evolutionary perspective. Physiology (Bethesda). 2017; 32(2): 112–125.
  19. Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016; 134(6): 441–450.
  20. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020; 16(4): 223–237.
  21. Mancia G. Hypertension: Does antihypertensive treatment have long-term benefits? Nat Rev Cardiol. 2012; 9(3): 130–132.
  22. Staessen JA, Thijisq L, Fagard R, et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens. 2004; 22(4): 847–857.
  23. Düsing R, Waeber B, Destro M, et al. Triple-combination therapy in the treatment of hypertension: a review of the evidence. J Hum Hypertens. 2017; 31(8): 501–510.
  24. Parati G, Kjeldsen S, Coca A, et al. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension. 2021; 77(2): 692–705.
  25. Chrysant SG. Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension. Postgrad Med. 2011; 123(6): 21–31.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl